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The Heart Institute of the University of São Paulo, Medical School is a referral center for the treatment of congenital
heart diseases of neonates and infants. In the recent years, the excellent surgical results obtained in our institution may be
in part due to modern anesthetic care and to postoperative care based on well-structured protocols.
The purpose of this article is to review unique aspects of neonate cardiovascular physiology, the impact of extracorporeal
circulation on postoperative evolution, and the prescription for pharmacological support of acute cardiac dysfunction
based on our cardiac unit protocols. The main causes of low cardiac output after surgical correction of heart congenital
disease are reviewed, and methods of treatment and support are proposed as derived from the relevant literature and our
protocols.
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The Heart Institute of University
of São Paulo Medical School is a refer-
ral center for the treatment of neonate
and pediatric congenital cardiopathies
for the state of São Paulo, as well as
for other regions of Brazil that do not
have access to specialized centers in
this type of care. Over the past 5 years,
2298 children have undergone cardiac
surgery here, including 1592 who un-
derwent surgeries with cardiopulmo-
nary bypass (CPB) and 706 without
CPB. In the last 12 months, for example,
the following surgeries were per-
formed: correction of an atrial septal
defect (ASD) (52), correction of a ven-
tricular septal defect (VSD) (59), cor-
rection of tetralogy of Fallot (94), trans-
position of the great arteries (TGA)
(23), and correction of atrioventricular
canal defects (AV canal ) (38).
Over the years, several protocols
especially concerning human re-
sources and intensive care have been
adopted in our ICU that have improved
postoperative results. Progress de-
pends on harmony among several fac-
tors such as accurate diagnosis, effi-
cient planning and scheduling of sur-
gery, and postoperative support. The
challenge for the multi-professional
team is to achieve the child’s full re-
integration into the family with pre-
served neurological, affective, psy-
chological, and social capacity. The
purpose of this study was to review
some unique aspects of neonatal car-
diovascular physiology, since some
of the children with heart disease are
neonates, as well as to review spe-
cific aspects of postoperative cardiac
care of neonates.
Neonatal  heart
The neonatal heart presents physi-
ological characteristics (Table 1) that
differ significantly from children of other
ages or from adults, and these should
be considered in the peri-operative ap-
proach1.
First, the contractile force of the
neonatal heart is less than that of the
adult because of a series of structural
alterations. The neonatal heart has 50%
fewer myofibers and a greater quantity
of nonconnective tissue, which limits
the systolic capacity, for example in
obstructive cardiopathies. The
myofibers are arranged in a chaotic or
nonlinear pattern. Additionally, the
neonatal myocardium has a smaller
number of sarcomeres and mitochon-
dria, and the calcium storage capacity
of the sarcoplasmatic reticulum is im-
mature. The immature sympathetic ner-
vous system reduces the myocardial
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storage of catecholamines. Moreover,
myocardial contractility during the first
week of life occurs because of circulat-
ing catecholamines, especially epineph-
rine, and adequate cardiac output is
maintained primarily by an elevated
heart rate. Newborns are more depen-
dent on the action of circulating cat-
echolamines for determining heart rate
than on preload for maintenance of ad-
equate cardiac output. In contrast, para-
sympathetic enervation is similar to that
of the adult, making the neonate more
susceptible to parasympathetic stimuli.
Second, the myocardial fibers have
greater length at baseline conditions,
resulting in less diastolic reserve for
volume overload. Therefore, contractil-
ity and ventricular compliance are ef-
fectively reduced, so the neonate myo-
cardium is near its functional limit at
baseline conditions.
Third, neonatal and fetal myocardial
function is characterized by ventricu-
lar interdependency2. An overload in
volume or pressure imposed on one of
the ventricles influences filling charac-
teristics of the other ventricle. In this
way, the dilated right ventricle increases
the filling pressure of the left one, and
this increased pressure then generates
elevated pressure on the right side in
order to maintain transatrial flow.
Fourth, immature fetal and neonatal
myocardium uses the metabolites of
carbohydrates and amino acids (glyco-
gen, glutamate, pyruvate, and lactate)
for contraction. Elevated stores of gly-
cogen and reduced numbers of mito-
chondria reflect adaptation to anaero-
bic conditions, with greater recovery
capacity and tolerance for hypoxic and
ischemic insults. Therefore, the neonate
is more vulnerable to hypoglycemia and
reacts to stress situations with rapid
alterations in pH, lactic acid, glycemia,
and temperature. These characteristics
are perpetuated beyond the neonatal
period. Gradual transformations occur
during all the first year of life, and com-
plete maturity of the myocardium oc-
curs only after 2 years of age3,4.
Cardiopulmonary  Bypass
The development of cardiopulmonary
bypass (CPB) has been essential for the
treatment of the great majority of con-
genital heart diseases. Management of
CPB for congenital heart disease dif-
fers from that for adults because of the
problems of aortopulmonary shunts,
the immature cardiovascular system,
and the eventual use of deep hypoth-
ermic circulatory arrest. During deep
hypothermic circulatory arrest, the
blood available in the systemic veins
(generally the cavas vein) is drained to
the oxygenator, which provides oxygen,
removes carbon dioxide, and reduces
the blood temperature. In the process,
the oxygenated blood returns to the
aorta by a system of pumps that gener-
ates continuous flow from the CPB to
the patient.
The plastic polyvinyl circuits of the
CPB system are full of a balanced solu-
tion made of colloids and crystalloids,
the composition of which varies accord-
ing to the age and weight of the pa-
tient, maintaining a pH and electrolyte
composition similar to that of the
plasma.
To reduce the metabolic rate and for
protection of tissues during CPB, mod-
erate (25oC to 32oC) or profound (15oC to
20oC) hypothermia is used. Profound
hypothermia permits reduction of flow
through the CPB, reduces trauma to
blood elements, and allows total circula-
tory arrest, usually during aortic arch
repair or in very small children. Hypoth-
ermia also preserves the highly energetic
phosphate stores and reduces liberation
of toxic cerebral neurotransmitters.
Different methods (eg, pH-stat, alpha-
stat) have been evaluated in the past
several decades for correction of acid-
base equilibrium during hypothermia,
primarily by comparing the neurologi-
cal evolution of patients. According to
du Plessis et al5, children undergoing
surgery using the alpha-stat method
have poorer cognitive development in
the late postoperative follow-up period
compared to those undergoing the pH-
stat method, probably because of the
acidification that the pH-stat method
provides, favoring vasodilatation and
homogeneous hypothermic cerebral
protection5.
In general, CPB alters all physiologi-
cal processes of the organism and may
lead to organic dysfunction of differ-
ent magnitudes. The morbidity associ-
ated with CPB is largely associated with
damage to blood elements and proteins
caused by blood gas alterations and the
prosthetic surface interface.
The exposure of blood to various
abnormal conditions is implicated in a
systemic inflammatory response. This
response includes interstitial edema,
coagulation cascade activation that
generates kallikrein and bradykinin, and
platelet consumption. Neutrophils and
monocytes are also activated to express
reactive cellular receptors and release
vasoactive and cytotoxic substances.
Activated complement proteins and
products from neutrophils and mono-
cytes mediate much of the inflamma-
tory response to CPB. Hemodilution
used during CPB, on the other hand,
reduces microcirculation resistance
Table 1 - Neonatal heart physiological considerations.
· Decreased myocardial contractile force.
· 50% reduction in myofibers and a greater quantity of nonconnective tissue.
· Myofibers present in a chaotic or nonlinear arrangement.
· Small number of sarcomeres, and mitochondria being immature for calcium storage.
· Immature sympathetic nervous system with reduced catecholamine storage.
· Cardiac output dependent on elevated heart rate and catecholamines rather than
preload.
· Parasympathetic enervation developed.
· Reduced diastolic reserve due to low ventricle compliance.
· Straight ventricular interdependency: overload in volume or pressure imposed on one
of the ventricles influences filling characteristics of the other ventricle.
· Myocardium utilizes carbohydrates and amino acids for contraction.
· Elevated stores of glycogen and reduced number of mitochondria suggestive of
adaptation to anaerobic conditions.
_______________________________________________________________________________________________
MAY-JUNE REV. HOSP. CLÍN. FAC. MED. S. PAULO 57(3):115-123, 2002
117
while exacerbating interstitial edema.
The formation of edema can be ex-
plained by the hemodilution (Table 2)
and by the inflammatory process un-
leashed by the passage of blood and
elements through the nonendothelial
surfaces of the CPB circuits. Permeabil-
ity of the capillary vessels is greater in
immature individuals than in adults.
Potent vasoactive substances are acti-
vated, including the anaphylatoxins
C3a and C5a, tumor necrosis factor, and
free radicals derived from oxygen, and
neutrophils are activated (Table 3). Con-
ventional ultrafiltration has been used
in an attempt to prevent this edema;
however, its effectiveness seems lim-
ited. In 1993, Naik and Elliot6,7 modified
the ultrafiltration system, placing the
hemoconcentrator between the aorta
and the right atrium immediately follow-
ing CPB (Table 4). With this modifica-
tion, the following have been noted: a
reduction in total body water content,
improved systolic function, increased
diastolic compliance, increased sys-
temic arterial pressure, hematocrit, fi-
brinogen, and total plasmatic protein,
and decreased levels of endothelial se-
rum cytokines and the C3a and C5a frac-
tions of complement6,7.
The more prolonged the CPB pro-
cedure is, the greater are the deleteri-
ous effects on these factors, since CPB
imposes an overload on the systemic
circulation that is often already com-
promised by the previous heart failure.
Immediate postoperative care and
monitoring
Adequate monitoring during
the postoperative period involves a
combination of clinical or auxiliary meth-
ods for evaluating the surgical correc-
tion, myocardial function, and the rela-
tionship between systemic and pulmo-
nary blood flow8. Standard monitoring
in the postoperative period is similar to
that during anesthesia and surgery.
Sometimes, depending on the clinical
evolution, more sophisticated monitor-
ing may be added to facilitate clinical
diagnosis and treatment. Standard
monitoring consists of ECG, direct ar-
terial pressure, temperature probe, and
central  venous pressure.  Pulse
oximeters and sometimes capnography
are useful for accompanying mechani-
cal ventilation. To obtain direct arterial
pressure, radial catheters are generally
preferable. Peripheral arterial catheters
may not precisely reflect aortic pres-
sure, particularly when placed in in-
fants’ feet and are even less accurate
in the presence of hypothermia. Tem-
perature monitoring is very important
for assessing the metabolism. Probes
can be placed in the rectum or near the
esophagus to provide adequate as-
sessment of body and core tempera-
ture. A nasopharyngeal probe gives an
estimate of brain temperature. The cen-
tral venous line is generally established
by insertion of a catheter utilizing the
Seldinger technique into the internal
jugular vein of choice. Depending on
the degree of severity and type of car-
diac disease, transthoracic or
transvenous measurement of pulmo-
nary and left atrial pressures may give
useful physiologic information. Cardiac
output can be also be determined by
thermodilution. In small children, the
traditional Swan-Ganz 7 or 5F catheter
cannot be used, but cardiac output can
be measured by means of a thermodilu-
tion 2F probe inserted by the surgeon
into the pulmonary artery. Newer tech-
niques including echocardiography
and on-line monitoring of arterial and
mixed venous saturation obtained by
fiberoptic catheters are increasingly
used in postoperative care.
In postoperative care of the pediat-
ric patient, clinical evaluation must be
complete and systematic. Conse-
quently, complications can be foreseen,
and catastrophic situations can be
avoided. Care should be initiated while
the child is still in the operating room,
with special attention to rewarming to
36.5ºC, control of bleeding, ventilation,
and acid-base and electrolyte balance.
It is very important during this phase
to stabilize cardiac function through
maintaining correct intravascular vol-
umes, adequate heart rate, and ad-
equacy of myocardial contractility.
The information concerning the an-
esthetic and surgical procedure that
should be transmitted in detail to the
multi-professional ICU team includes
surgical technique, type of anesthesia,
perfusion and aortic clamping time, wa-
ter and colloid balance, diuresis, venous
and arterial catheter placement, pace-
maker wire and mediastinal or thoracic
drainage tube positioning, ventilatory
Table 2 –  Excessive hemodilution
during and after cardiopulmonary
bypass may cause:
_____________________________________
· More requirement for blood
transfusion.
· Greater use of inotropic agents.
· Undesirable hemodynamic
performance.
· Depressed myocardial contractility.
___________________________________________
Table 3 - Causes of excessive edema in neonates and small children under
cardiopulmonary bypass:
· Permeability of the capillary vessels is greater in immature individuals than for adults.
· Potent vasoactive substances are activated during CPB including anaphylatoxins, C3a
and C5a, TNF, and other cytokines that contribute to capillary leaking.
Table 4 - Modified ultrafiltration in pediatric open heart operation results in:
· Reduction in total body water content.
· Improvement in systolic function.
· Increase in diastolic compliance.
· Increase in systemic arterial pressure.
· Elevation in hematocrit, fibrinogen, and total plasmatic protein concentration.
· Decrease in the cytokines C3a and C5a fraction of complement.
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conditions, acid-base balance, heart rate
and arrhythmias, and coagulation and
vasoactive medication in use9.
Supplementary monitoring, includ-
ing left atrial and pulmonary arterial
pressure and serial echocardiography,
is indicated in all children undergoing
more serious or complex cardiopathy
correction that present: a) significant
myocardial dysfunction (left coronary
anomaly, transposition of the great ar-
teries, hypoplastic left heart); b) pul-
monary arterial hypertension during or
prior to the operative period (total
anomalous drainage of the pulmonary
veins, aortic arch interruption, truncus
arteriosus communis); c) valvoplasty
or correction of an atrioventricular ca-
nal defect with a residual defect of mi-
tral insufficiency.
Cardiovascular function
The cardiovascular function of a
child can be considered adequate in the
postoperative period when cardiac out-
put is sufficient to supply the demands
for cellular oxygen.
The main determining factors of car-
diac output are preload, afterload, con-
tractility, heart rate, and diastolic func-
tion1. Other indirect factors, such as
anxiety, pain, temperature, hemoglobin
level, endogenous, and exogenous cat-
echolamines, and blood biochemical
composition, can alter the myocardial
oxygen supply-demand relationship in
addition to affecting the cardiac out-
put10.
During the postoperative period,
cardiovascular dysfunction repre-
sented by low cardiac output can de-
velop for a series of reasons. First are
all of the pre-operative conditions, in-
cluding the structural defect itself and
the functional cardiac state, the gen-
eral birthing conditions, transfer from
hospital to specialized care centers, the
detail and efficiency of planning for the
surgery, and associated complications
such as respiratory insufficiency, infec-
tion, and metabolic and electrolyte dis-
turbances. Secondly, the dysfunction
is dependent on the surgery performed,
degree of ventricle muscle incision,
placement of corrective patches, myo-
cardial protection, CPB time and aortic
clamping, level of hypothermia during
CPB, use of total circulatory arrest, type




tion can be evaluated by clinical ex-
amination, related tissue oxygen in-
dexes, echocardiography and hemody-
namic and/or radioisotope evalua-
tion10.
Important clinical signals for the
evaluation of cardiac output are per-
spiration, adequate level of conscious-
ness, coloring and temperature of ex-
tremities, thermal gradient between
knees and feet, central and peripheral
thermal gradient, amplitude of periph-
eral pulse, capillary filling, arterial pres-
sure, and urinary output. Accordingly,
cardiac output is considered adequate
when there is no cold perspiration or
psychomotor agitation, the members
of extremities are warm and colored,
the feet are hotter than the knees, the
central-peripheral thermal gradient is
less than 4oC, the peripheral pulse is
easily palpable, capillary filling is sat-
isfactory, arterial pressure is within the
normal limits for the age group, and
urinary output is greater than l mL/kg/
hour. It is important to remember that
adequate peripheral vasodilatation
only occurs after the fourth postop-
erative hour, with normal re-establish-
ment of tissue perfusion around the
sixth postoperative hour10.
Among the related tissue oxygen
indexes, lactate is a marker of anaero-
bic metabolism and tissue energy defi-
cit. It reflects hypoxia, ischemia, or
aggressive action of a toxic tissue
agent. Values for serum lactate above
2.0 – 3.0 mmol/L reflect significant evi-
dence of tissue hypoxia. Following
total circulatory arrest, profound hy-
pothermia (< 20oC), or low cardiac out-
put, serum lactate levels commonly
exceed 6-10 mmol/L. Also regarding
tissue oxygenation, the calculation of
the arterial-venous oxygen differential,
as well as the consumption, transport,
and peripheral extraction of oxygen
can be used in evaluation of low car-
diac output in small children. Clinical
outcome can be related to the relation-
ship of these indexes to normal levels.
Measurement of troponin could be
a specific marker for the evaluation of
myocardial injury, according Taggart
et al11. They found that infants under-
going cardiac surgery with CPB had
elevated levels of troponin during the
postoperative period that remained el-
evated for 72 hours. Infants undergo-
ing cardiac surgery without CPB, did
not have elevated levels of troponin.
On the other hand, infants from both
groups had elevated creatine kinase
MB isoenzyme levels that progres-
sively decreased over 72 hours.
Two-dimensional and Doppler
echocardiography are valuable tools
for postoperative cardiac functional
and structural evaluation. These meth-
ods permit analysis of cardiac cham-
bers and operative results, detection
of residual defects, evaluation of po-
sition and function of valvar prosthe-
sis, segmental and global myocardial
analysis, calculation of shortening and
the ventricular ejection fraction, and
estimation of pressures inside cardiac
chambers.
Cardiac catheterization for angiog-
raphy or manometry of cardiac cavi-
ties is a traditional and accepted
method that may be used in the post-
operative period. The principal indica-
tions for cardiac catheterization are
evaluation of systemic-pulmonary
shunt permeability, for example in the
Blalock-Taussig operation, evaluation
of pulmonary vascularization follow-
ing reunification or centralization of
pulmonary arteries, measurement of
residual pressure gradients after am-
plification of the right or left atrium,
and evaluation of cardiopulmonary
anastomosis, for example in the Fontan
procedure or modified Glenn opera-
tion. During the neonatal period, new
types of cardiac hemodynamic proce-
dures are occasionally indicated for
therapy or for investigations into re-
sidual defects that cannot be clarified
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using other methods of diagnosis.
Direct measurement of cardiac out-
put can be obtained by invasive and
noninvasive methods. The noninvasive
method uses a relationship between
expected oxygen consumption and the
arterial-venous oxygen differential.
However, the method may be incorrect
when used to determine the expected
consumption in the postoperative pe-
riod. Noninvasive methods for deter-
mining oxygen consumption calculated
by nomograms are dependent on heart
rate, age, sex, and body temperature;
some of these factors are quite variable
in the first hours following CPB12.
As previously mentioned, the ther-
modilution method for determining car-
diac output is most frequently used in
postoperative care; in pediatrics, the
data are indexed to body surface area.
Accordingly, the cardiac index is con-
sidered normal in children when it is
above 3 L/min/m2, moderately reduced
between 2.0 to 3.0 L/min/m2, and se-
verely reduced when lower than 2.0 L/
min/m2. In general, the cardiac index
tends to be lower in the fourth postop-
erative hour in relation to the immedi-
ate postoperative period and increases
after the 9th or 12th hours. Kirklin et
al12 correlated a greater number of hos-
pital deaths with a cardiac index below
2.0 L/min/m2 in a postoperative study
of 174 children under the age of 3
months.
Low cardiac output
Low postoperative cardiac output
is primarily caused by reduction in myo-
cardial contractility caused by one of
the mechanisms or factors above men-
tioned. Severe myocardial dysfunction
can be observed, for example, in more
complex congenital heart disease that
demands a lengthy CPB procedure and
aortic clamping. Left anomalous coro-
nary artery in the pulmonary trunk, hy-
poplastic left heart syndrome, trans-
position of the great arteries, severe
tetralogy of Fallot, and severe pulmo-
nary hypertension are all associated
with significant risk of poor cardiac func-
tion after surgery.
Secondarily, hemodynamic instabil-
ity is caused by inadequate intravas-
cular volume due to a series of factors
including an endothelial inflammatory
process resulting from the CPB proce-
dure, which transfers fluids to the in-
terstitial area (primarily in the first 24
hours); vasodilatation during the re-
warming period after CPB (4 to 6 hours
postoperatively); urinary output; and
active blood loss.
Control of intravascular volume and
indirectly of preload should promote
more adequate systolic volume, accord-
ing to the Frank-Starling law. In the ab-
sence of more severe valvar injury, the
final diastolic pressure of the ventricles
corresponds to the mean pressure of
the atrium; therefore, volume can be
controlled via right and left atrial pres-
sures. During the postoperative period,
the atrial pressure should remain
around 15 mmHg, although it can reach
18 mmHg in the right atrium and 20
mmHg in the left when there is hyper-
trophy or hypocontractility, partial ob-
struction in the ventricular outflow, or
pulmonary artery hypertension.
Afterload is a third factor influenc-
ing cardiac output. It can be elevated
by vasoconstriction secondary to CPB,
hypothermia, excessive endogenous
catecholamines, or administration of
vasoactive amines. The heart with any
degree of myocardial dysfunction can
experience significant reduction of myo-
cardial fiber length and consequently
its systolic volume when subjected to
any increase in afterload.
Heart rate is dependent on factors
such as use of digital or beta-blocking
agents in the preoperative period, type
of surgery, perioperative rhythm distur-
bances, volume, temperature, pain, anxi-
ety, anemia, metabolic disturbances,
and use of vasoactive agents with chro-
notropic action.
Alternatively, postoperative myo-
cardial edema could be responsible for
ventricular diastolic restriction.
Treatment
Therapeutic measures for low post-
operative cardiac output include 3 con-
comitant and related procedures: 1) di-
agnosis, 2) reduction in metabolic de-
mand, 3) adequate tissue perfusion and
oxygen transport 1.
Suspected cardiac dysfunction
should be promptly investigated for
etiological diagnosis by clinical or
supplemental methods so specific and
effective conduct can be adopted.
Reduction in metabolic demand re-
quires the use of measures that favor
adequate temperature and reduction in
respiratory workload. Initial measures,
even during diagnostic investigation
can be adopted to maintain body tem-
perature around 36.5oC 10.
Ventilation and respiratory mechan-
ics play a primary role in the improving
the hemodynamic state of the postop-
erative patient through use of positive
end expiratory pressure and adjustment
of PaCO2 and pH. Factors that influence
the hemodynamic state include general
anesthesia, pulmonary retraction,
edema due to residual injury, reduced
functional residual capacity leading to
alterations in gas exchange, pulmonary
compliance, abnormalities in the venti-
lation-perfusion ratio, and intrapulmo-
nary shunts 10.
Mechanical ventilation is main-
tained until bleeding is controlled, he-
modynamics are stabilized, adequate
body temperature attained, metabolic
disturbances are corrected, and acid-
base balance is achieved.
The necessary support for ad-
equate tissue perfusion and oxygen
transport is basically related to con-
comitant employment of inotropic and
vasodilator agents (Table 5). Inotropic
agents are the primary therapeutic tools
for treating low cardiac output. The
principal sympathomimetic amines are
represented by dopamine and epineph-
rine or synthetic agents such as iso-
proterenol and dobutamine. All of these
agents act through stimulation of myo-
cardial beta-adrenergic receptors, in-
creasing cyclic adenylate and cyclic
adenosine monophosphate (cAMP)13.
Dopamine increases myocardial
contractility through several mecha-
nisms including stimulation of postsyn-
aptic beta 1-adrenergic receptors, in-
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creasing liberation of norepinephrine in
the myocardial presynaptic sympa-
thetic storage sites and decreasing en-
zymatic degradation and reabsorption
of norepinephrine. Dopamine also acts
as a pulmonary and systemic vasocon-
strictor through action in alpha 1- and
alpha 2-postsynaptic receptors. Be-
cause of its action on dopamine adren-
ergic receptors, dopamine acts as a re-
nal, spleen, coronary, and cerebral va-
sodilator. In animal research, dopamine
has been shown to be less efficient in
neonates than in adult animals, prob-
ably because of the greater clearance,
reduced myocardial adrenergic enerva-
tion, lower density of myocardial beta
1-adrenergic receptors, and differing
maturation among peripheral alpha re-
ceptors and myocardial beta 1 and
dopaminergic receptors. In neonates,
dopamine increases cardiac output,
heart rate, and systemic arterial pres-
sure10. Dopamine is indicated in moder-
ately low cardiac output, especially
when there is water retention from the
cardiac insufficiency itself or because
of the CPB procedure. In doses of 1 to
2 mg/kg/min, dopamine acts as vasodi-
lator on the mesenteric and renal circu-
lation. In doses between 2 and 10 mg/
kg/min, it acts on myocardial beta 1 re-
ceptors producing increased contrac-
tility and coronary flow with conse-
quent improvement in mean arterial pres-
sure and cardiac index. However,
Driscoll et al.14, observed that the neo-
natal myocardium seems less sensitive
to the action of dopamine than does
the myocardium of older children, and
more elevated doses are necessary to
obtain the same effects. In another
study, Lang et al. 15  observed that
dopamine increases heart rate, cardiac
index, and systemic arterial pressure
after pediatric cardiac surgery when
given in doses greater than 15 mg/kg/
min but does not have significant ac-
tion on systemic vascular resistance.
In higher doses, dopamine raises pul-
monary resistance, which is why it is
not used in cases of previous pulmo-
nary artery hypertension.
Dobutamine is a synthetic sym-
pathomimetic amine, beta 1-adrenergic
agonist. It differs from dopamine by not
liberating endogenous norepinephrine
and has little peripheral action.
Dobutamine increases cardiac output
and reduces systemic vascular resis-
tance and ventricular filling pressure.
Since it exerts a positive chronotropic
effect, elevating heart rate, its use could
be limited in the postoperative cardiac
surgery period in children and neo-
nates 12. Dobutamine is indicated for low
cardiac output when not accompanied
by severe hypotension. In sepsis with-
out cardiac failure, dobutamine is the
therapy of choice, and when cardiac
compromise already exists, it can be in-
dicated when associated with a vaso-
constrictor like norepinephrine. In-
crease in cardiac output and reduction
in systemic vascular resistance can be
obtained by starting dobutamine at low
doses such as 2.5 mg/kg/min. In gen-
eral, doses of 2 to 20 mg/kg/min are ef-
fective.
Isoproterenol is a synthetic ana-
logue of norepinephrine. It is an ago-
nist that stimulates myocardial beta 1-
adrenergic receptors, with direct inotro-
pic and chronotropic action, and pro-
motes peripheral vasodilatation medi-
ated by beta 2-adrenergic receptors. It
increases cardiac output and systolic
arterial pressure, and it vasodilates re-
nal, spleen, and skeletal muscle tissue
with a reduction in diastolic arterial
pressure and systemic vascular resis-
tance13 . Isoproterenol is indicated
mainly in the presence of sinusal brady-
cardia or transitory atrioventricular
block. In the neonatal population, it can
be indicated for controlling low cardiac
output secondary to persistent arterial
hypertension in the newborn. The ini-
tial dose of isoproterenol is 0.01 to 0.05
mg/kg/min  for symptomatic bradycardia
and 0.05 to 0.1 mg/kg/min as a positive
inotropic agent. With the increase in
heart rate, an accentuated increase in
myocardial oxygen consumption and
transitory myocardial ischemia may oc-
cur. Sinus tachycardia ventricular
arrhythmias due to compromised coro-
nary flow can appear with more elevated
doses.
Epinephrine is an endogenous cat-
echolamine that is liberated from the
adrenal medulla and derived from nore-
pinephrine. It acts on alpha-, beta 1- and
beta 2-adrenergic receptors. Depending
on the dose, it increases heart rate and
systolic arterial pressure, decreases di-
astolic arterial pressure, and relaxes the
peripheral vascular bed. At high doses
the alpha-adrenergic effect predomi-
nates, producing skin, gastrointestinal,
and renal perfusion10. Epinephrine is
indicated for low cardiac output accom-
panied by severe systemic arterial hy-
potension that compromises coronary
perfusion, especially in postoperative
cardiac surgery with cardiogenic or sep-
tic shock that is not responsive to
dopamine and dobutamine. It is also
effective in cardiac arrest. At doses of
Table 5 - Agents utilized in pharmacological manipulations for increasing right




· Prostaglandin E1 (PGE1).
· Prostacyclin (PGI2).
· Ultra-short-acting intravenous vasodilators: adenosine and adenosine triphosphate.
· Inhaled nitric oxide.
Table 6 -  Phosphodiesterase inhibitors—cardiovascular effects:
· Increase myocardial contractility.
· Increased lusitropic activity (energy-dependent diastolic relaxation).
· Vasodilating properties.
· Reduce ventricular wall stress.
· Reduce filling pressures.
· Reduce impedance to ventricular ejection.
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0.03 to 0.1 mg/kg/min, beta 1 and beta 2
effects are predominant. At doses of
0.1 to 0.2 mg/kg/min, there is a mixed
alpha and beta effect. At doses above
0.2 up to 1 mg/kg/min, the alpha re-
sponse is predominant. Ventricular ar-
rhythmia possibly caused by
subendocardic ischemia and peripheral
vasoconstriction may be observed with
this agent.
Norepinephrine it is a local adrener-
gic neurotransmitter. It has beta 1 and
alpha action, which increases the sys-
tolic arterial pressure as much as the
diastolic pressure. Cardiac output can
increase or decrease depending on the
myocardial reserve. A starting dose of
0.05 to 0.1 mg/kg/min has been recom-
mended.
Another possibility for therapy in
the control of low cardiac output is the
use of phosphodiesterase inhibitors,
introduced into clinical practice in 1984.
Phosphodiesterase agents, such as
amrinone and milrinone inhibitors, are
non-glycoside non-sympathomimetic
agents that selectively inhibit the cy-
clic phosphodiesterase nucleotide, in-
creasing myocardial and vascular
cAMP, independent of the beta recep-
tors. Elevation of cAMP increases con-
traction through calcium regulation by
2 mechanisms: first, by activation of the
kinase protein that facilitates the rapid
entry of calcium through calcium chan-
nels, and second, by activation of the
calcium stores of the sarcoplasmic
reticulum. Accordingly, the phosphodi-
esterase inhibitors have 3 actions: in-
creasing inotropism and contractility,
increasing arteriolar and venous vasodi-
latation, and increasing ventricular re-
laxation during diastole (Table 6).
Amrinone increases the cardiac index
and decreases left ventricular end dias-
tolic pressure, pulmonary capillary pres-
sure, and right atrial pressure in con-
gestive heart failure and in postopera-
tive low cardiac output. Additionally,
when associated with dobutamine, it
has greater action on the elevation of
the cardiac index and on the reduction
in systemic vascular resistance, and it
does not significantly increase heart
rate16.
Milrinone is considered to be 10 to
30 times more potent than amrinone. It
does not elevate myocardial consump-
tion and is a coronary vasodilator.
Milrinone is metabolized primarily in the
kidneys, necessitating dosage correc-
tion in the presence of renal failure.
Amrinone is metabolized by the liver
and excreted primarily by the kidneys.
Phosphodiesterase inhibitors can
be indicated for low cardiac output with
myocardial dysfunction and elevated
systemic vascular resistance, but with-
out severe arterial hypotension. Pedi-
atric dosages of amrinone are variable
in the literature but have been cited as:
0.75 mg/kg bolus dose (over time for 2-
3 doses) followed by infusion of 5-10
mg/kg/min for maintenance. In neo-
nates, bolus doses of 3 to 4.5 mg/kg are
used, followed by 5 to 15 mg/kg/min of
continuous infusion. Since the half-life
of this agent is relatively long (3 to 15
hours), special attention must be given
to those children that already have sys-
temic arterial hypotension. In adults
with normal renal function, the bolus
of milrinone is 50 mg/kg over 10 minu-
tes, followed by 0.375 to 0.75 mg/kg/min
infusion. Side effects can include hy-
potension caused by vasodilatation,
necessitating administration of fluids;
thrombocytopenia, usually 7 to 10 days
after its administration; and elevation
of hepatic enzymes, as described for
amrinone infusion (Table 7).
Vasodilators for low cardiac out-
put are adjuvants to inotropic therapy,
reducing systemic arterial resistance
and enhancing ventricular ejection.
Sodium nitroprusside in doses of 0.5
to 8 mg/kg/min acts to increase vascu-
lar relaxation through cGMP, causing
arteriolar and venous vasodilatation.
The start of action after endovenous
administration occurs in a few minutes.
The primary metabolites of nitroprus-
side are thiocyanate and cyanide, which
have been detected during prolonged
infusion13.
Sodium nitroprusside is the vasodi-
lator most used, not only for control-
ling systemic and pulmonary hyperten-
sive states, but also for reducing
afterload in low cardiac output, prima-
rily after cardiac surgery. Nowadays for
pediatric postoperative cardiac pa-
tients, sodium nitroprusside has pro-
gressively been replaced by phos-
phodiesterase inhibitors, which are not
only inotropic but also are arteriolar and
venous vasodilators.
Nitroglycerine in doses of 0.5 to
20 mg/kg/min is a vasodilator that acts
by releasing nitric oxide. The main he-
modynamic effect is vasodilation with
reduction in ventricular filling pres-
sures. Nitroglycerine is indicated for
situations of increased preload and
signs of pulmonary and systemic
venous congestion.
The utilization of inhaled nitric oxide
in postoperative period
Nitric oxide (NO) produced by the
endothelial cells exerts important func-
tions on cardiovascular system. In lung
tissue, the maintenance of blood ves-
sels in a relaxed status is fundamentally
important, especially in the presence of
previous pulmonary hypertension and/
or right ventricle dysfunction. Right ven-
tricular (RV) dysfunction is frequently
observed in infants and children in the
postoperative period. Pharmacological
and ventilatory manipulations are di-
rected at increasing RV inotropism, uti-
Table 7 -  Pharmacology of amrinone and milrinone.
                   Variable measured Amrinone (IV) Milrinone(IV)
Loading dose, mg/kg (per approved product labeling) 1.5 (0.72x2) 0.050
Loading dose (maximally effective) 3.0 0.075
Infusion rate, mg/kg/min (labeling) 5-10 0.375-0.75
Incompatible with dextrose solutions Yes No
Average half-life in CHF patients (h) 5-8 2-3
Incidence of thrombocytopenia 2.6% 0.4%
Incidence of ventricular tachycardia/fibrillation 0.8% 3.6%
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lizing inotropic drugs as outlined above,
by optimizing RV preload, and by con-
trolling pulmonary vascular resistance
(PVR). In the presence of RV dysfunc-
tion, control of PVR is extremely impor-
tant, since RV output is very sensitive
to the variations of afterload. As previ-
ously discussed, the most commonly
used agents for controlling PVR are so-
dium nitroprusside, nitroglycerin, and
phosphodiesterase inhibitors17. Prostag-
landin E1 (PGE1) and prostacyclin (PGI2)
both have a pulmonary vasodilating ef-
fect. The problem is that the effects of
these drugs are not limited to the pulmo-
nary circulation. Because of the lack of
specificity of vasodilator drugs on the
pulmonary bed, newer pharmacological
methods of controlling elevated PVR are
being recommended. Inhaled NO and
ultra-short-acting intravenous vasodila-
tors, such as adenosine and adenosine
triphosphate, represent new modalities
for treating acute pulmonary hyperten-
sion in postoperative pediatric cardiac
patients (Table 8). Although nonselec-
Table 8 - Inhaled nitric oxide in post-op after cardiac surgery: Main indication:
Pulmonary hypertension accompanied of right ventricular dysfunction
· Correct metabolic disturbances.
· Provide sedation and adequate ventilation.
· Consider using phosphodiesterase inhibitors first.
· Start inhaled NO with low doses.
· Closely monitor with echocardiography.
· Remove NO carefully.
tive, NO is rapidly inactivated by hemo-
globin; therefore, when NO is inhaled,
the systemic circulation is protected from
its vasodilating properties. When we
administered inhaled NO to a group of
patients after cardiac surgery, we ob-
served a significant pulmonary vasodi-
latation and no clinically significant ef-
fects on systemic pressure 18. These same
effects have also been observed in chil-
dren after cardiac surgery19. In more se-
vere situations of RV dysfunction ac-
companied by pulmonary hypertension,
we have used small doses of inhaled NO
(3 to 5 parts per million) in our postop-
erative children. Although several stud-
ies have demonstrated the vasodilating
properties of NO on pulmonary circula-
tion, recommendation for its use as a
routine agent during cardiac surgery in
pediatric patients suffering pulmonary
hypertension is still under investiga-
tion20.
RESUMO RHCFAP/3081
AULER Jr. JOC e col. - Cuidados
pediátricos pós-operatórios de cirur-
gia cardíaca.  Rev. Hosp.  Clín. Fac.
Med. S. Paulo 57(3): 2002.
O Instituto do Coração da Faculda-
de de Medicina da Universidade de São
Paulo  é centro de excelência para trata-
mento das cardiopatias congênitas que
abranjam o período neonatal e
pediátrico. Nos últimos anos, parte dos
excelentes resultados cirúrgicos da Ins-
tituição devem-se ao progresso da
anestesia e a estruturação dos cuida-
dos pós-operatórios por meio de pro-
tocolos bem definidos.
Este artigo se propõe a revisar aspec-
tos de interesse da fisiologia
cardiovascular do neonato, as repercus-
sões orgânicas da circulação extra-
corpórea, o pós-operatório imediato, in-
cluindo avaliação cardiovascular e a te-
rapia farmacológica desta Unidade. Será
apresentada uma revisão das causas mais
comuns de baixo débito; cirurgias para a
correção das cardiopatias congênitas e
propostas de métodos diagnósticos e
terapêuticos, baseados na literatura es-
pecializada e protocolos da Unidade.
DESCRITORES: Pediatria.   Cardio-
patia congênita. Cirurgia. Pós-opera-
tório.
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